• Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death • Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of Medicine

TREMFYA® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis

• More than 90% of patients surveyed who underwent bladder removal or received BCG report negative impact on most aspects of their lives • Among patients treated with BCG, three-quarters describe managing the treatment-related physical symptoms as humiliating • Patients and urologists point to the importance of advancing treatments that may better reflect patient preferences and quality‑of‑life considerations

CAPLYTA® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials Among the secondary endpoints for the adjunctive MDD therapies evaluated, CAPLYTA® demonstrated no weight gain compared to placebo plus antidepressant therapy Featured in a late-breaking presentation at the 2026 NEI Spring Congress, analysis provides indirect comparisons to help inform treatment decisions in the absence of head-to-head clinical trials